Evidence map›Paper›PMID 34711042›Full record

ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2021

[Community-acquired pneumonia: selection of empirical treatment and sequential therapy. SARS-CoV-2 implications].

J González Del Castillo, A Julián-Jiménez, F J Candel

Open access · diamondAbstract readReview
In one paragraph

Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. [New predictive models of bacteremia in the emergency department: a step forward].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  2. Decalogue for the selection of oral antibiotics for lower respiratory tract infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

J González Del CastilloJuan González del Castillo. Servicio de Urgencias. Hospital Clínico San Carlos. Madrid, Spain. jgonzalezcast@gmail.com.
A Julián-Jiménez
F J Candel
Hospital Clínico San Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumonia is a major cause of global mortality in developed countries. The adequacy of the antibiotic treatment is essential for the good evolution of the patients. When selecting the antimicrobial, the severity of the patient, the characteristics of the antibiotics, and the profile of the patient to be treated should be considered. Recommendations for the selection of antibiotic treatment may differ between the patient who requires admission and the one who can be treated as outpatient. Beta-lactams, fluoroquinolones, and macrolides are the most widely used antimicrobials in this last circumstance. However, not all are the same in terms of efficacy, safety and ecological impact. This review delves into the aforementioned aspects to improve decision-making and offers concrete recommendations for the selection of antibiotic treatment. Likewise, it includes recommendations for performing sequential therapy. Finally, a brief review is made about the impact of SARS-CoV-2 infection on this pathology.

Indexed as

Community-Acquired InfectionsCOVID-19Pneumoniabeta-LactamsHumansSARS-CoV-2beta-LactamsCommunity-acquired pneumoniaOral antibiotic therapySequential therapy

Identifiers

PMID34711042
PMCPMC8638761
OpenAlexW3209774153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.